Fool me once, shame on you; fool me twice, shame on me; fool me thrice, hit the sell button.
OK, so I just made up that last part, but yesterday, Protalix BioTherapeutics'
You'll recall -- or maybe not, considering how long ago it was -- that almost two years ago, the FDA asked Protalix and marketing partner Pfizer
After the duo submitted a second marketing application, the FDA set a goal of making an approval decision by Feb. 1. Unfortunately, the agency asked for more clinical data during the second review, and decided it needed until May 1 to make a decision.
Orphan drugs have become a lucrative business as BioMarin Pharmaceutical
Protalix uses plant cells to manufacture the drug. The novelty has its advantages, lower costs among others, but the novelty seems to be coming with added scrutiny from the FDA. Since the manufacturing side tends to be a black box for investors, it's difficult to assess the risk of another rejection.
The delay could be nothing. It could be the last one. This could be an excellent entry point. But "coulds" aren't very reassuring. Unfortunately, there's just no way to know if Protalix has finally submitted enough data to convince the FDA to approve taliglucerase alfa.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of BioMarin Pharmaceutical and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Simplest Biotech Growth Portfolio Ever
Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.
Is This Orphan Drugmaker in Trouble?
Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?
Can Protalix Revolutionize This Orphan Disease?
The latest results in Protalix's pipeline may be from a phase 1 trial, but don't let that fool you. If successful, PRX-112 could run laps around Shire and Sanofi and catch the attention of larger partners, including Pfizer.